Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma

Hui Wen Lue, Brook Cole, Soumya A.M. Rao, Jennifer Podolak, Ahna Van Gaest, Carly King, Christopher A. Eide, Beth Wilmot, Changhui Xue, Paul T. Spellman, Laura M. Heiser, Jeffrey W. Tyner, George V. Thomas

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


The intracytoplasmic tyrosine kinase Src serves both as a conduit and a regulator for multiple processes required for the proliferation and survival cancer cells. In some cancers, Src engages with receptor tyrosine kinases to mediate downstream signaling and in other cancers, it regulates gene expression. Src therefore represents a viable oncologic target. However, clinical responses to Src inhibitors, such as dasatinib have been disappointing to date. We identified Stat3 signaling as a potential bypass mechanism that enables renal cell carcinoma (RCC) cells to escape dasatinib treatment. Combined Src-Stat3 inhibition using dasatinib and CYT387 (a JAK/STAT inhibitor) synergistically reduced cell proliferation and increased apoptosis in RCC cells. Moreover, dasatinib and CYT387 combine to suppress YAP1, a transcriptional co-activator that promotes cell proliferation, survival and organ size. Importantly, this combination was well tolerated, and caused marked tumor inhibition in RCC xenografts. These results suggest that combination therapy with inhibitors of Stat3 signaling may be a useful therapeutic approach to increase the efficacy of Src inhibitors.

Original languageEnglish (US)
Pages (from-to)44675-44687
Number of pages13
Issue number42
StatePublished - 2015


  • Cancer
  • Kidney
  • Kinase inhibitors
  • STAT3
  • Src

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this